Tag Archives: Federal Circuit

Life Science Patenting to Iancu – “We need help too!”

Posted on December 2, 2018 by Warren Woessner

In his remarks presented at the recent 10th Annual Patent Law & Policy Conference at Georgetown University Law School, USPTO Director Andrei Iancu outlined the analytical framework for the new, eagerly awaited, PTO Guidance on patent eligible subject matter. Although … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged Alice, Andrei Iancu, Bilski, Diehr, Federal Circuit, Mayo, Myriad, s. 101, USPTO | Leave a comment

Kumar v. Iancu – The Dangers of an Overstuffed Preamble/Note on 37 CFR Part 4.

Posted on November 9, 2018 by Warren Woessner

On November 7, 2018, the Fed. Cir. issued a summary affirmance of the PTAB’s interference decision of September 6, 2016, in Kumar v. Sung (Patent Interference 14/322,039) which found that the claims of U.S. Pat. No. 8,541,422 were obvious over … Continue reading →

Posted in Obviousness | Tagged Attorney General Matt Whitaker, clopidogrel, Federal Circuit, intellectual property, Kumar v. Sung, PATB, Plavix, President Trump, USPTO | Leave a comment

Yeda Res. and Dev. v. Mylan – “We don’t need no Stinkin’ Prior Art”

Posted on October 18, 2018 by Warren Woessner

The quote is from “Treasure of the Sierra Madre” when a bandido leader is trying to convince Bogart that his gang are Federales, and Bogie asks to see their badges. In the context of Yeda Res. and Dev. v. Mylan, … Continue reading →

Posted in Prior Art | Tagged Federal Circuit, KSR, MPEP, Mylan, Obviousness, PTAB, Warren Woessner, Yeda | Leave a comment

UCB, Inc. v. Accord Healthcare, Inc. – Can a Racemic Mixture be a “Lead Compound.”

Posted on October 16, 2018 by Warren Woessner

UCB v. Accord, Appeal no. 2016-2610 et al. (Fed. Cir., May 23, 2018) may be headed to the Supreme Court, which prompted me to take another look at this opinion. This was a decision in Hatch-Waxman litigation, in which a … Continue reading →